Get the Stockscreener App
3.25
3.56%
-0.12
After Hours:
3.29
0.04
+1.23%
Black Diamond Therapeutics Inc stock is traded at $3.25, with a volume of 1.11M.
It is down -3.56% in the last 24 hours and up +27.95% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$3.37
Open:
$3.39
24h Volume:
1.11M
Relative Volume:
1.11
Market Cap:
$185.04M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.7287
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+10.54%
1M Performance:
+27.95%
6M Performance:
+81.56%
1Y Performance:
-44.44%
1-Day Range:
$3.23
$3.43
1-Week Range:
$2.885
$3.43
52-Week Range:
$1.195
$6.23
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
3.25 | 182.76M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
BRAF + NSCLC Pipeline Landscape Report 2025: Novel Therapies, Market Outlook, and Clinical Advances - The Globe and Mail
Multi factor analysis applied to Black Diamond Therapeutics Inc.Dividend Hike & Technical Buy Zone Confirmation - Newser
Is it time to cut losses on Black Diamond Therapeutics Inc.2025 Biggest Moves & Short-Term Trading Alerts - Newser
Is Black Diamond Therapeutics Inc. stock entering bullish territory2025 Major Catalysts & High Accuracy Trade Alerts - Newser
Will earnings trigger a reversal in Black Diamond Therapeutics Inc.Earnings Overview Report & Reliable Entry Point Alerts - Newser
Is Black Diamond Therapeutics Inc. stock reversal real or fakePortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Black Diamond Therapeutics Inc. stock outlook for YEARTrade Exit Summary & Stepwise Trade Signal Implementation - Newser
Key resistance and support levels for Black Diamond Therapeutics Inc.Quarterly Market Summary & Precise Trade Entry Recommendations - Newser
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? - Nasdaq
Is a relief rally coming for Black Diamond Therapeutics Inc. holdersQuarterly Trade Report & Daily Market Momentum Tracking - Newser
Is this a good reentry point in Black Diamond Therapeutics Inc.Market Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
Can you recover from losses in Black Diamond Therapeutics Inc.Trade Risk Report & Free Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-09-12 06:14:21 - Newser
Detecting price anomalies in Black Diamond Therapeutics Inc. with AILayoff News & Safe Entry Point Alerts - Newser
Black Diamond Therapeutics Inc. stock momentum explainedWeekly Risk Summary & Growth Focused Stock Pick Reports - Newser
What Fibonacci levels say about Black Diamond Therapeutics Inc. reboundNew Guidance & Free Accurate Trade Setup Notifications - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Coverage Initiated at Guggenheim - MarketBeat
How sentiment analysis helps forecast Black Diamond Therapeutics Inc.2025 Sector Review & AI Based Buy/Sell Signal Reports - Newser
has black diamond therapeutics inc. found a price floorJuly 2025 Weekly Recap & Fast Momentum Entry Tips - Newser
Full technical analysis of Black Diamond Therapeutics Inc. stockDividend Hike & AI Optimized Trading Strategy Guides - Newser
Will Black Diamond Therapeutics Inc. bounce back from current supportTrade Volume Report & Scalable Portfolio Growth Methods - Newser
Has Black Diamond Therapeutics Inc. formed a bullish divergenceBreakout Watch & High Accuracy Swing Trade Signals - Newser
Black Diamond Therapeutics Inc. stock trend forecastTrend Reversal & Consistent Growth Stock Picks - Newser
What’s next for Black Diamond Therapeutics Inc. stock price2025 Top Gainers & Low Risk Entry Point Guides - Newser
Black Diamond Therapeutics Inc. stock trendline breakdownWeekly Investment Report & Weekly Hot Stock Watchlists - Newser
Trend analysis for Black Diamond Therapeutics Inc. this weekStop Loss & Accurate Trade Setup Notifications - Newser
Will Black Diamond Therapeutics Inc. benefit from macro trendsTrade Ideas & Daily Profit Maximizing Tips - Newser
Order flow analysis tools used on Black Diamond Therapeutics Inc.Bond Market & AI Powered Market Trend Analysis - Newser
Predicting Black Diamond Therapeutics Inc. trend using moving averagesPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Has Black Diamond Therapeutics Inc. found a price floor2025 Earnings Impact & Expert Approved Momentum Trade Ideas - Newser
Tools to monitor Black Diamond Therapeutics Inc. recovery probabilityWatch List & Fast Entry Momentum Alerts - Newser
Detecting support and resistance levels for Black Diamond Therapeutics Inc.Market Sentiment Review & Safe Capital Growth Stock Tips - Newser
Should you wait for a breakout in Black Diamond Therapeutics Inc.Inflation Watch & Consistent Return Investment Signals - Newser
Black Diamond Therapeutics Inc. stock retracement – recovery analysis2025 Market Sentiment & Reliable Intraday Trade Alerts - Newser
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):